Current advances in microbial-based cancer therapies

Shahbaz, Areej; Mahmood, Tehreem; Javed, Muhammad Uzair; Abbasi, Bilal Haider

doi:10.1007/s12032-023-02074-x

Cited by 3 publications

(1 citation statement)

References 160 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specific gut bacteria have been associated with improved or reduced responses to immunotherapy drugs, highlighting the potential for manipulating the microbiome to enhance treatment outcomes in cancer patients [217,218]. This emerging field of research, known as microbial oncology, holds promise for revolutionizing cancer treatment strategies and improving patient outcomes [219][220][221].…”

Section: Impact Of Microbiome On Treatment Outcomesmentioning

confidence: 99%

Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases

Kamel,

Aleya,

Alsubih

et al. 2024

JPM

View full text Add to dashboard Cite

Infectious diseases have long posed a significant threat to global health and require constant innovation in treatment approaches. However, recent groundbreaking research has shed light on a previously overlooked player in the pathogenesis of disease—the human microbiome. This review article addresses the intricate relationship between the microbiome and infectious diseases and unravels its role as a crucial mediator of host–pathogen interactions. We explore the remarkable potential of harnessing this dynamic ecosystem to develop innovative treatment strategies that could revolutionize the management of infectious diseases. By exploring the latest advances and emerging trends, this review aims to provide a new perspective on combating infectious diseases by targeting the microbiome.

show abstract

Section: Impact Of Microbiome On Treatment Outcomesmentioning

confidence: 99%

Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases

Kamel,

Aleya,

Alsubih

et al. 2024

JPM

View full text Add to dashboard Cite

show abstract

Gut microbiota and immunotherapy of renal cell carcinoma

Bibbò,

Porcari,

Del Vecchio

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Immunoadjuvants in Cancer Immunotherapy

Talati,

Chouhan,

Sharma

et al. 2024

Advances in Medical Diagnosis, Treatment, and Care

View full text Add to dashboard Cite

Immunoadjuvants are crucial components of cancer immunotherapy that enhance immune responses against tumors. This chapter explores the underlying mechanisms and clinical uses of immunoadjuvants in cancer immunotherapy. Toll-like receptor agonists and STING agonists are two types of immunoadjuvants that activate immune cells and promote anti-tumor immunity. Cytokine-based immunoadjuvants have potential toxicity and off-target effects, but nanotechnology enables precision delivery to minimize these issues. Personalized approaches, biomarker discovery, and predictive modeling are important for optimizing treatment responses. Overall, immunoadjuvants are essential tools in cancer immunotherapy for generating strong and long-lasting anti-tumor immune responses. In conclusion, immunoadjuvants are critical components of cancer immunotherapy, playing a vital role in boosting strong and durable anti-tumor immune responses.

show abstract

Current advances in microbial-based cancer therapies

Cited by 3 publications

References 160 publications

Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases

Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases

Gut microbiota and immunotherapy of renal cell carcinoma

Immunoadjuvants in Cancer Immunotherapy

Contact Info

Product

Resources

About